Cancer and Bone Society
VII International Meeting on Cancer Induced Bone Disease
Heriot Watt University, Edinburgh, UK
June 29 - July 2, 2008
Click here to download a PDF of the schedule.
Sunday June 29 | Monday June 30 | Tuesday July 1 | Wednesday July 2
Sunday 29th June
15.00 – 16.30 CABS Board Meeting
Carnegie Room A
16.55 – 17:00 Welcome and opening of the meeting
Main Auditorium
17.00 – 18.30 Plenary Session I
Chair: Rob Coleman & Toshiyuki Yoneda TBC
Main Auditorium
17:00 – 17:30 Preparing the soil – the bone marrow niche
Gregory Mundy, Nashville, USA
17:30 – 18:00 Tumour-bone cell interactions in malignancy
Theresa Guise, Charlottesville, USA
18:00 – 18:30 Developments in bone targeted treatment of cancer
David Roodman, Pittsburgh, USA
19.00 – 21.00 Opening Reception - Exhibition Hall
Monday 30th June
8.00 – 8.50 Educational Workshop - Main Auditorium
Chair: Ingunn Holen
Animal models – how do they help and when do they mislead?
Philippe Clezardin, Lyon, France
Gabri van der Pluijm, Leiden, Netherlands
08.50 – 10.30 Plenary Session II - The Metastatic Problem - Main Auditorium
Chair: Greg Mundy TBC & Thomas Anderson TBC
08.50 – 09:15 Mathematical modeling to evaluate cancer cell invasion
Alexander Anderson, Dundee, Scotland
09:15 – 09:40 Proteolytic enzymes
Gill Murphy, Cambridge, UK
09:40 – 10:05 Bone pain associated with cancer colonization
Toshi Yoneda, Osaka, Japan
10:05 – 10:30 PTHrP and non-collagenous bone proteins
Matt Gillespie, Melbourne, Australia
10.30 – 11.00 Morning Coffee
11.00 – 11.50 Plenary Session III - Tumour Cell Biology and Bone Metastasis
Chair: Eva Corey TBC & Marco Cecchini TBC
Main Auditorium
11:00 – 11:25 Prostate cancer stem cells and the metastatic process
Norman Maitland, York, UK
11:25 – 11:50 Wnt signalling in Bone Metastasis
Gregory Clines, Charlottesville, USA
11.50 – 13.00 Oral Communication Session I
Chair: Toshio Matsumoto & Clemens Lowik TBC
Main Auditorium
11:50 – 12:00
OC16
Improved clinical outcomes in premenopausal women with early, endocrine-responsive breast cancer receiving zoledronic acid in combination with adjuvant endocrine therapy.
Michael Gnant, Vienna, Austria
12:00 – 12:10
OC1
Translating a novel urine test for early detection and accurate assessment of bone abnormalities
Darren Hillegonds, Livermore, USA
12:10 – 12:20
OC2
Efficacy, Pharmacokinetics, and Safety of a Cathepsin K (Cat K) Inhibitor in the Suppression of Bone Resorption in Women with Breast Cancer and Established Bone Metastases: a 4-week, Double-Blind, Randomized Controlled Trial
Anish Mehta, Christchurch, New Zealand
12:20 – 12:30
OC3
Farnesoid X receptor (FXR): a new marker for the prediction of bone metastases in breast cancer
Fabrice Journe, Brussels, Belgium
12:30 – 12:40
OC4
Number and sites of bone lesions and history of skeletal-related events (SREs): do these parameters correspond with skeletal morbidity and mortality in patients with bone metastases (mets) from hormone-refractory prostate cancer (HRPC)?
Fred Saad, Ontario, Canada
12:40 – 12:50
OC10
Prognosis and Skeletal Disease Course in Patients With Bone Metastases From Breast Cancer (BC) and Normal Baseline Levels of N-Telopeptide of Type I Collagen (NTX)
Allan Lipton, Hershey, USA
12:50 –13:00
OC6
Endo180 function in metastatic prostate cancer bone lesions
Giolanta Kogianni, London, UK
13.00 – 14.00 Meet the Professor Case Discussion (Working Lunch)
Prostate cancer
Main Auditorium
Oncologist
Nick James, Birmingham, UK
Bone specialist
Eugene McCloskey, Sheffield, UK
14.00 – 15.45 Plenary Session IV - Prediction of bone disease and metastasis
Chair: Philippe Clezardin & Bill Dougal TBC
Main Auditorium
14:00 – 14:35 Genetic predisposition to bone disease
Stuart Ralston –Edinburgh, UK
14:35 – 15:10 Genetic signatures and prediction of bone metastasis
Jan Klijn, Rotterdam, Holland
15:10 – 15:45 Circulating Tumour cells and tumour DNA
Jeffrey Smerage, Ann Arbor, USA
15.45 - 16.15 Afternoon Tea
16.15 - 17.45 Satellite symposium I – Novartis Oncology
Main Auditorium
18.00 - 21.00 Poster Party
Buffet and discussions
Tuesday 1st July
8.30 – 9.25 Educational Session
Chair: Matthew Smith TBC
Main Auditorium
Clinical trial design – How to establish a new treatment as a new standard of care
Judith Bliss, Institute for Cancer Research, London
9.30 – 10.20 Plenary Session V - Bone biology and the Bone Microenvironment
Chair: Mike Rogers TBC & Hannu Monkkonen TBC
Main Auditorium
09:30 – 09:55 RANK ligand signaling system in malignancy
Peter Croucher, Sheffield, UK
09:55 – 10:20 Osteoblast inactivation in myeloma
Toshio Matsumoto, Tokushima, Japan
10:20 – 10:50 Oral Communication Session II
Chair: Chris Wynne
Main Auditorium
10:20 – 10:30
OC7
Inhibiting Dickkopf-1 (Dkk-1) Prevents the Development of Osteolytic Bone Disease in Multiple Myeloma
Debby Heath, Sheffield, UK
10:30 – 10:40
OC8
Essential role of host bone marrow-derived stromal cells in the initial establishment and progression of multiple myeloma
Jessica Fowler, Nashville, USA
10:40 – 10:50
OC9
A role for B cell suppression in a pre-clinical model of multiple myeloma
Jessica Fowler, Nashville, USA
10.50 – 11.15 Morning Coffee
11.15 - 12.00 Plenary Session VI - Bone Biology in Solid Tumours
Chair: Theresa Guise & Gabri van der Pluijm TBC
Main Auditorium
11:15 – 11:40 Osteoblast activation in solid tumours
Marco Cecchini, Bern, Switzerland
11:40 – 12:05 Bone cell- tumour cell interactions in prostate cancer
Eva Corey, Seattle, USA
12.05 – 13.05 Oral Communication Session III
Chair: Kathy Weilbacher & Matt Gillespie TBC
Main Auditorium
12:05 – 12:15
OC5
Prevention of anastrozole induced bone loss with monthly oral ibandronate during adjuvant breast cancer therapy. Two year results from the ARIBON study.
Jim Lester, Sheffield, UK
12:15 – 12:25
OC11
Effect of Anastrozole on Bone Mineral Density after One Year of Treatment: Results from Bone Sub-Study of the International Breast Cancer Prevention Study (IBIS-II)
Shalini Singh, London, UK
12:25 – 12:35
OC12
Specific Inhibition of the VEGF Homolog Placental Growth Factor is Protective against Osteolytic Bone Metastasis in Mice.
Lieve Coenegrachts, Leuven, Belgium
12:35 – 12:45
OC13
Development of the European Organization for Research and Treatment of Cancer Bone Metastases Module (BMM) (EORTC QLQ-BM22)
Amanda Hird, Toronto, Canada
12:45 – 12:55
OC14
Osteolysis and the generation of osteoclast-myeloma hybrid cells are related to the myeloma cell-induced collapse of the Vascular Bone Remodeling Compartments
Thomas Anderson, Southern Denmark, Denmark
12:55 – 13:05
OC15
Potential influence of zoledronic acid on primary tumour response during neoadjuvant chemotherapy for breast cancer
Matthew Winter, Sheffield, UK
13.10 -14.00 Meet the Professor Case Discussion (Working Lunch)
Breast cancer
Main Auditorium
Radiation Oncologist
David Dodwell, Leeds, UK
Bone Specialist
Jean-Jacques Body, Brussels, Belgium
14.15 -15.45 Satellite symposium II – Amgen
RANKL inhibition in cancer-induced bone disease: an update
Main Auditorium
15.45 – 16.15 Afternoon Tea
16.15 – 17.05 Plenary Session VII - Functional Imaging of the Skeleton
Chair: Jean-Jacques Body TBC & Oyvind Bruland TBC
Main Auditorium
16:15 – 16:40 Developments in Preclinical Imaging
Clemens Löwik, Leiden, Holland
16:40 – 17:05 PET scanning of the Skeleton
Ignac Fogelman, London, UK
18:30 – 00:00 Conference Dinner
Prestonfield Manor House
DRESS CODE: Smart Casual
18:30 Coaches depart Heriot Watt University for Prestonfield
18:30 Coaches depart Marriott Dalmahoy for Prestonfield
19:00 Drinks Reception on Lawns at Prestonfield
19:30 Dinner is served
00:30 Coaches depart Prestonfield for Dalmahoy and Heriot Watt
Wednesday 2nd July
9.00 – 10.40 Plenary Session VIII - Skeletal Therapeutics
Chair: David Roodman TBC & Gregory Clines TBC
Main Auditorium
09:00 – 09:25 Bisphosphonates: where do they go and what do they do?
Anke Roelofs, Aberdeen, UK
09:25 – 09:50 Use of biomarkers to monitor therapy in metastatic bone diseases
Patrick Garnero, Lyon, France
09:50 – 10:15 Bone targeted therapy
Robert Coleman, Sheffield, UK
10:15 – 10:40 Radioisotope treatment of bone metastases
` Oyvind Bruland, Oslo, Norway
10.40 – 11.10 Morning Coffee
11.10 - 12.40 Satellite symposium III – MSD
Emerging Therapeutic Approaches in the Prevention of Bone Metastases: Cathepsin K Inhibition
Main Auditorium
12.50 -13.50 Meet the Professor Case Discussions (Working Lunch)
Multiple myeloma
Haematologist
John Ashcroft, Leeds, UK
Bone specialist
Eugene McCloskey, Sheffield, UK
14.00 - 14.30 CABS Annual General Meeting
Main Auditorium
14.30 – 16.10 Plenary Session VIIII - Controversies
Chair: Peter Croucher TBC & Eugene McCloskey TBC
Main Auditorium
14:30 – 14:55 What can the patients tell us about the effectiveness of treatment – the Importance of patient reported outcomes
Lesley Fallowfield, Brighton, UK
14:55 – 15:20 Haematopoeitic cell and growth factor – tumour cell interactions
Kathy Weilbacher, St Louis, USA
15:20 – 15:45 Is the antitumour efficacy of bisphosphonates clinically relevant?
Ingunn Holen, Sheffield, UK
15:45 – 16:10 Protecting the normal skeleton – who, when and why
Matt Smith, Boston, USA
16.10 Closing remarks
Robert Coleman, Sheffield, UK
Main Auditorium